Objectives: To report the linezolid activity, resistance mechanisms and epidemiological typing of selected isolates observed during the 2016 Zyvox V R Annual Appraisal of Potency and Spectrum (ZAAPS) programme.
Introduction
Linezolid was the first-in-class oxazolidinone agent approved for treating Gram-positive infections. Its clinical approval occurred in early 2000 by the FDA and in 2001 by EMA and other regulatory agencies. 1 Following regulatory approval, the in vitro activity of linezolid was monitored through several programmes, including Zyvox V R Annual Appraisal of Potency and Spectrum (ZAAPS) and Linezolid Experience and Accurate Determination of Resistance (LEADER), which surveyed the drug activity, emergence of resistance and resistance mechanisms, and the epidemiology of selected isolates in a broader scale during 2004-16.
2,3
The ZAAPS programme included Gram-positive pathogens responsible for infections in patients from several medical institutions located in many countries worldwide, except for the USA, which was monitored by LEADER. Both programmes reported on the consistent and potent in vitro activity of linezolid and, most importantly, emerging resistance mechanisms, including plasmidmediated cfr, 4, 5 cfr(B) 6 and optrA. 7 These programmes also reported on the complex evolution of the oxazolidinone resistance mechanisms that occurred among CoNS during the last 12 years. 1, 3 In the final year (2016) of the ZAAPS programme, this study documents the continued evolution of oxazolidinone resistance mechanisms and reports the emergence of optrA in Streptococcus gallolyticus and its presence in Enterococcus faecalis as the most common resistance mechanism.
Materials and methods

Clinical isolates
The ZAAPS programme was part of the SENTRY Antimicrobial Surveillance Program, which monitors antimicrobial resistance and the prevalence of pathogens causing bloodstream infections, community-acquired pneumonia, pneumonia in hospitalized patients, skin and skin structure infections, urinary tract infections and intra-abdominal infections (six main study protocols). 2 Participating sites followed instructions specific for each V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
protocol to select and include consecutive and unique (one per patient) isolates that were deemed clinically relevant, based on local criteria, until they reached a target number of 250-500 pathogens per site (depending on medical centre size).
2
Isolates that met the selection criteria for each protocol (n " 8325) were initially identified by the participant laboratory (76 centres; 42 countries; 5 continents) using local practices and submitted to the coordinating monitoring laboratory (JMI Laboratories, North Liberty, IA, USA) ( Table 1) . The monitoring laboratory confirmed bacterial identifications using phenotypic and biochemical methods, per Murray et al. 8 All streptococci (nonpneumococci), enterococci other than E. faecalis and Enterococcus faecium, and CoNS were subjected to the MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) system. In addition, all organisms showing questionable phenotypic and/or biochemical results had their identification confirmed by MALDI-TOF MS.
Antimicrobial susceptibility testing
Isolates were tested for susceptibility by broth microdilution using 96-well panels following the CLSI guidelines. 9 MIC testing was performed using frozen-form panels manufactured by JMI Laboratories that contained CAMHB (2.5%-5% lysed horse blood added for testing streptococci). Isolates exhibiting initial linezolid MIC results of 4 mg/L were re-tested in a 96-well panel containing an extended dilution range (1-128 mg/L) for linezolid. Bacterial inoculum density was monitored by colony counting to ensure an adequate number of cells for each testing event. MIC values were validated by concurrent testing of quality control strains. 10 MIC interpretations were based on the CLSI and EUCAST breakpoint criteria, except for tigecycline MIC interpretation to which FDA-approved criteria were applied. [10] [11] [12] Detecting linezolid resistance mechanisms and epidemiological typing
Isolates that showed elevated MIC results for linezolid (MICs of 4 mg/L) were selected for further characterization at the central laboratory. These isolate genomes were sequenced on a MiSeq sequencer following the manufacturer's instructions (Illumina, San Diego, CA, USA). Assembled genomes were subjected to proprietary software (JMI Laboratories) to screen for the presence of cfr, cfr(B), cfr(C) and optrA. DNA sequences associated with 23S rRNA and ribosomal proteins (L3, L4 and L22) were extracted and analysed for the presence of mutations. 6, 13 Isolates exhibiting linezolid MIC results of 4 mg/L had the seven housekeeping genes necessary for assigning MLST (ST) extracted from assembled genomes. In addition, isolates from the same species recovered from the same medical centre were subjected to PFGE analysis. 2 
Results and discussion
The vast majority of Gram-positive pathogens (99.8%) included in ZAAPS 2016 were inhibited by linezolid at the respective breakpoints ( Table 2 ). The central tendency (modal MIC) for linezolid against these Gram-positive isolates was 1 mg/L, except for CoNS against which the linezolid modal MIC result was 0.5 mg/L. This MIC value tendency also remained consistent against staphylococci showing a methicillin-resistant phenotype or E. faecium displaying a VRE phenotype (Tables 2 and 3 ). All but two streptococci were inhibited by linezolid at 2 mg/L.
Comparative analysis showed that linezolid, daptomycin, tigecycline and the glycopeptides were active against MRSA (96.7%-100.0% susceptible) when applying current clinical breakpoints (Table 3) . Similar susceptibility results (92.0%-100.0% susceptible) were observed against the entire CoNS collection. Overall, high susceptibility rates (98.5%-100.0% susceptible) were noted for all drugs tested against the E. faecalis collection, except for erythromycin (intrinsically resistant) 14 and levofloxacin (for urinary tract infections only). 10, 12 In contrast, E. faecium exhibited an acceptable (.90.0%) susceptibility rate for linezolid, daptomycin and tigecycline. This species showed a vancomycin non-susceptibility rate of 29.8%.
Overall, most agents tested against Streptococcus pneumoniae showed suboptimal coverage (,90.0% susceptible), except for linezolid, amoxicillin/clavulanate, levofloxacin, tigecycline and vancomycin (Table 3 ). Penicillin and ceftriaxone were active (91.0%-92.9% susceptible) when parenteral breakpoints were applied. The penicillin non-susceptibility rates (penicillin MICs of 0.12 mg/L) for S. pneumoniae were: Asia-Pacific (APAC) (47.8%) followed by Latin America (36.3%), Europe (29.6%) and Canada (20.0%) (data not shown). Non-susceptibility rates for ceftriaxone (EUCAST breakpoint) were highest in the APAC region (27.8%), with rates of 12.8%-15.6% in the other areas (data not shown). S. pneumoniae displaying non-susceptibility to levofloxacin were only observed in the APAC region (4.1%) and Europe (1.7%). Linezolid, ceftriaxone, daptomycin, levofloxacin, teicoplanin, tigecycline and vancomycin were active against viridans-group streptococci (Tables 2 and 4 ). The S. aureus isolate carried the cfr gene and belonged to ST72, whereas the four S. epidermidis isolates showed drug target alterations in several sites (Table 4) . Multiple oxazolidinone target site alterations have become commonplace among CoNS in the last decade.
1,3 S. epidermidis isolates that were non-susceptible to linezolid were mostly from Italy and belonged to ST2; this clonal type represents an important lineage that has been detected in several medical centres worldwide. 15 A recent report described the dissemination of ST2 S. epidermidis isolates among Italian medical centres as well. 16, 17 A total of eight E. faecalis from Guatemala City (4), Durango (2), Taipei (1) and Paris (1) were non-susceptible to linezolid (MICs of 4 mg/L) and all harboured optrA (Table 4) . Isolates recovered from Guatemala City all had the same ST (ST256), as did the E. faecalis from Durango (ST480). Isolates associated with these STs were recovered previously from humans. 18, 19 E. faecalis isolates carrying optrA usually show genetic lineage diversity with occasional clonal dissemination within medical centres, as reported here and in previous studies. 19, 20 Only two E. faecium (Rome) isolates were linezolid resistant (MICs of 8 mg/L) and these isolates had 23S rRNA Ex-USA linezolid resistance surveillance JAC mutations (Table 4) . These E. faecium were clonally related (ST117) and the PFGE profile demonstrated by these isolates was observed among linezolid-non-susceptible E. faecium isolates from this site on several occasions (Table 4) . One S. gallolyticus (linezolid MIC of 4 mg/L) and 1 Streptococcus mitis (linezolid MIC of 16 mg/L) displayed elevated MIC results for linezolid. While the former carried optrA, 13 the latter had 23S rRNA mutations (Table 4) . Streptococcal isolates displaying nonsusceptible MIC results for linezolid were rarely detected throughout the ZAAPS/LEADER programmes, with one Streptococcus oralis in 2002 (G2576T), 21 one S. pneumoniae in 2010 (L4 mutation), 22 one Streptococcus sanguinis from 2011 (23S rRNA mutations) 23, 24 and one S. sanguinis from 2013 (G2576T) 25 detected during the programmes' histories. Other streptococci demonstrating linezolid non-susceptibility were previously reported outside ZAAPS/ LEADER, [26] [27] [28] including the presence of cfr in a Streptococcus suis. 28, 29 The optrA gene was also previously detected in S. suis isolates recovered from pigs 30 and this study reports the emergence of optrA in a S. gallolyticus causing human infection. 13 These data show that linezolid has consistent potency against Gram-positive pathogens and emphasize the relevance of surveillance for detecting emerging resistance and for monitoring the evolution of resistance and associated pathogens. The final year of the ZAAPS programme (2016) reports the importance of optrA as an oxazolidinone resistance determinant with its emergence in S. gallolyticus and its dissemination and dominance as a resistance gene in E. faecalis. In previous studies, linezolid resistance among enterococci was mainly due to alterations in 23S rRNA, which remains the case for E. faecium.
1 However, optrA has become more common in E. faecalis. This change can be explained, at least partially, by the lack of or a low fitness cost associated with the presence of optrA compared with the presence of mutations in general. 31, 32 It is interesting to note that cfr has also been associated with a generally low fitness cost in S. aureus, 33 and the occurrence of cfr in S. aureus in this study (0.03%) was lower than the presence of optrA in E. faecalis (1.5%). A broader analysis shows that the prevalence of cfr in S. aureus during the last 3 years of LEADER and ZAAPS (2014-16) combined was 0.02% (5/20 349) but 62.5% (5/8) among isolates with linezolid MIC values of 4 mg/L. 2, 3, 7 In a similar analysis, the occurrence of optrA in E. faecalis was 0.4% (14/3437) but 100.0% (14/14) in isolates with linezolid MIC values of 4 mg/L. cfr and optrA were initially detected in human specimens in these surveillance studies (ZAAPS/LEADER) in 2007 4 and 2006 (China; R. E. Mendes and L. Deshpande, unpublished data), respectively. These surveillance data suggest that optrA may be disseminating in E. faecalis more rapidly than cfr in S. aureus, implying a greater transferability of optrA. 31 Surveillance and infection control will be important strategies to detect and contain the plasmid-mediated optrA resistance gene from disseminating.
